MwanzoMYGN • NASDAQ
add
Myriad Genetics, Inc.
$ 27.09
Baada ya Saa za Kazi:(0.00%)0.00
$ 27.09
Imefungwa: 17 Jul, 19:08:57 GMT -4 · USD · NASDAQ · Kanusho
Bei iliyotangulia
$ 27.39
Bei za siku
$ 26.96 - $ 27.58
Bei za mwaka
$ 13.82 - $ 27.82
Thamani ya kampuni katika soko
2.45B USD
Wastani wa hisa zilizouzwa
elfu 819.00
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
NASDAQ
Kwenye habari
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Mac 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 202.20M | 11.59% |
Matumizi ya uendeshaji wa biashara | 165.50M | -1.78% |
Mapato halisi | -26.00M | 52.47% |
Kiwango cha faida halisi | -12.86 | 57.40% |
Mapato kwa kila hisa | -0.01 | 95.24% |
EBITDA | -12.20M | 54.98% |
Asilimia ya kodi ya mapato | -0.39% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Mac 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 104.30M | 32.53% |
Jumla ya mali | 1.11B | -5.03% |
Jumla ya dhima | 350.50M | 4.91% |
Jumla ya hisa | 760.00M | — |
hisa zilizosalia | 90.51M | — |
Uwiano wa bei na thamani | 3.26 | — |
Faida inayotokana na mali | -6.18% | — |
Faida inayotokana mtaji | -7.57% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Mac 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -26.00M | 52.47% |
Pesa kutokana na shughuli | -18.60M | 43.98% |
Pesa kutokana na uwekezaji | -7.10M | -120.52% |
Pesa kutokana na ufadhili | -8.80M | -79.59% |
Mabadiliko halisi ya pesa taslimu | -35.30M | -969.70% |
Mtiririko huru wa pesa | -19.35M | 56.10% |
Kuhusu
Myriad Genetics, Inc. is an American genetic testing and precision medicine company based in Salt Lake City, Utah, United States. Myriad employs a number of proprietary technologies that permit doctors and patients to understand the genetic basis of human disease and the role that genes play in the onset, progression and treatment of disease. This information is used to guide the development of new products that assess an individual's risk for developing disease later in life, identify a patient's likelihood of responding to a particular drug therapy, assess a patient's risk of disease progression and disease recurrence, and measure disease activity. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
1991
Makao Makuu
Tovuti
Wafanyakazi
2,700
